The aim of the current study was to evaluate the effectiveness and tolerability of escitalopram on both depressive symptoms and sleep problems of depressive patients.
An observational, open-label, 3-month study was conducted in Greece.
Effectiveness was assessed using the CGI-S and AIS (Athens Insomnia Scale) scales. Tolerability was evaluated by spontaneously reported adverse events and treatment discontinuation rates.
The study included 2,103 patients (mean age 51 ¡À 15 years, 64.0 % women).
Patients showed significant improvement during the treatment period for both depressive symptoms and sleep problems. Mean CGI-S scores decreased from 4.2 ¡À 0.8 to 2.2 ¡À 1.0 and total AIS score decreased from 13.6 ¡À 4.9 to 3.5 ¡À 3.8 (repeated measures analysis of variance Hotelling's test, p < 0.001). The positive effect of escitalopram treatment was significant both on ¡°night sleep?and ¡°behaviour on the following days? Moreover, the percentage of patients suffering from insomnia (AIS score >=6) decreased from 89.1 % to 22.1 % (Cochran's Q test p < 0.001). Escitalopram was also well tolerated, as 1909 (90.8 % ) patients successfully completed the study and 39 patients (1.85 % ) discontinued due to adverse events.
Escitalopram combines significant effectiveness on both depressive symptoms and sleep problems with good tolerability.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址:北京市海淀区学院路29号 邮编:100083 电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700 |